NCT02672839View on ClinicalTrials.gov

A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
DRUG

LGD-6972 Solution

15 mg of LGD-6972

DRUG

LGD-6972 Capsules

15 mg LGD-6972

Trial Locations (1)

45227

Medpace, Inc, Cincinnati

Sponsors

Collaborators (1)

Medpace, Inc.
All Listed Sponsors
collaborator

Medpace, Inc.

INDUSTRY

lead

Ligand Pharmaceuticals

INDUSTRY

NCT02672839 - A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation | Biotech Hunter | Biotech Hunter